[
    {
        "id": "Case503",
        "patient_info": "At 2 years of age, a child with a history of high-risk Brief Resolved Unexplained Events presenting as recurrent witnessed seizure\u2011like episodes is under evaluation after a nondiagnostic chromosomal microarray. Because a genetic etiology is suspected, whole\u2011exome sequencing has been ordered, with a plan for follow\u2011up with a genetic counselor after results are available. The evaluation was initiated by a nurse practitioner, and a genetic counselor has already been seen prior to testing and will review results once they arrive. Family history notes a sibling from a consanguineous family, which raises the possibility of an autosomal recessive condition. The patient is insured under BCBS FEP."
    },
    {
        "id": "Case811",
        "patient_info": "At 7 weeks of age, a previously healthy neonate presents with a movement-disorder phenotype including dystonia, ataxia, and hemiplegia, suggesting a neuromuscular or neurologic abnormality; CMA was previously performed and non-diagnostic, and whole exome sequencing is now being pursued under BCBS_FEP. The test was ordered by a general pediatrician, with a genetic counselor seen before testing and planned to review results after they are received. There is a sibling with multiple congenital anomalies in the family history, which supports broader genomic testing in this infant."
    },
    {
        "id": "Case17",
        "patient_info": "A 4-year-old child with an unexplained epileptic encephalopathy that began before age three is being evaluated after chromosomal microarray testing was non-diagnostic; the pediatric neurologist has ordered whole-exome sequencing to pursue a genetic diagnosis, with a genetic counselor having discussed the plan with the family. There is a brother with unexplained developmental regression in the family, and the case is insured through Cigna."
    },
    {
        "id": "Case884",
        "patient_info": "At 32 weeks\u2019 gestation, a fetus is being evaluated for a neuromuscular\u2013neurological phenotype described as dystonia, ataxia, and related movement abnormalities, with the evaluation led by a Developmental Pediatrician. Prior testing included karyotype analysis, which was non-diagnostic, and there is a family history of a sibling with multiple congenital anomalies, raising concern for a hereditary neurodevelopmental syndrome. In light of this, whole-exome sequencing (WES) has been ordered to be performed prenatally through the patient\u2019s UHC plan, with genetic counseling declined by the family, and the team aims to clarify a genetic etiology to guide perinatal planning and care."
    },
    {
        "id": "Case647",
        "patient_info": "NO\nPrenatal context with neurodevelopmental regression is unrealistic, since a 17-week fetus cannot exhibit developmental regression or neurodevelopmental risk."
    },
    {
        "id": "Case710",
        "patient_info": "NO\nA prenatal fetus context is invalid because age_years must be -1 to describe a fetus, but this case lists a 73-year-old patient with intrauterine fetal demise/stillbirth."
    },
    {
        "id": "Case373",
        "patient_info": "At 25 weeks' gestation, a fetus with multiple congenital anomalies not clearly fitting a single genetic syndrome is being evaluated by the obstetrician. Following non-diagnostic FISH testing, the plan includes whole-exome sequencing (WES) to search for a genetic etiology. The patient's paternal line is notable for a father, assigned male at birth, with a history of breast cancer, contributing to familial risk. The case is insured by UHC. No genetic counseling is documented in the record, and arrangements for prenatal genetic counseling and perinatal management will depend on WES results and ongoing obstetric findings."
    },
    {
        "id": "Case120",
        "patient_info": "NO\nA 15-year-old adolescent being managed by a neonatologist is not realistic under the age\u2013provider rules."
    },
    {
        "id": "Case661",
        "patient_info": "NO\nA 2-week-old neonate cannot have multiple primary breast cancers, making the scenario biologically impossible."
    },
    {
        "id": "Case13",
        "patient_info": "The patient is a neonate, 0 weeks old, evaluated for multiple congenital anomalies not specific to a well-delineated genetic syndrome, referred by a General Pediatrician for diagnostic workup; prior karyotype testing was non-diagnostic. The plan is to pursue whole-exome sequencing (WES) to identify a molecular etiology, with BCBS_FEP coverage. The family history includes a sibling with unexplained developmental regression, unrelated to autism or epilepsy. A genetic counselor met with the family before testing and will return to discuss results after they are received."
    },
    {
        "id": "Case955",
        "patient_info": "NO\nAdult 60-year-old is being managed by a pediatric neurologist, which violates the age\u2013provider rule that adults should not be managed by pediatric specialists."
    },
    {
        "id": "Case452",
        "patient_info": "At 3 weeks of age, a neonate presented with coloboma. Prior karyotype testing was non-diagnostic. There is a sibling with dysmorphic features in the family, suggesting a possible hereditary syndrome. The evaluation was initiated by a nurse practitioner, and a genetic counselor discussed the plan with the family. Whole-exome sequencing is planned to identify a genetic etiology, given the non-diagnostic karyotype. The patient is insured through Cigna."
    },
    {
        "id": "Case333",
        "patient_info": "NO\nGlobal developmental delay is a pediatric diagnosis, and applying it to a 59-year-old is unrealistic."
    },
    {
        "id": "Case457",
        "patient_info": "At 70 years of age, the patient was referred by their Primary Care Physician for evaluation of multiple congenital anomalies not specific to a well-delineated genetic syndrome, with a prior non-diagnostic karyotype. The family history includes a sister with a history of triple-negative breast cancer. A genetic counselor has seen the patient multiple times, and whole-exome sequencing has been ordered to investigate a possible genetic etiology. The plan includes post-test genetic counseling and results review, with the patient insured through BCBS_FEP."
    },
    {
        "id": "Case794",
        "patient_info": "At 21 weeks' gestation, a fetus is being evaluated for suspected congenital hypotonia; a General Pediatrician ordered whole-exome sequencing after a prior chromosomal microarray, which was non-diagnostic. There is a family history of global developmental delay in a mother, suggesting a possible hereditary neurodevelopmental condition. A genetic counselor was offered but declined. The plan is to pursue WES with follow-up, and the pregnancy is insured through Cigna."
    },
    {
        "id": "Case3",
        "patient_info": "A 17-year-old with a diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer is being evaluated, with a cardiologist having ordered whole-exome sequencing after prior FISH testing was non-diagnostic; there is a maternal relative with breast cancer diagnosed at age 50 or younger, which raises concern for an inherited cancer predisposition, and the patient has seen a genetic counselor multiple times as part of ongoing family-risk assessment. The genetic testing plan centers on WES to identify pathogenic or likely pathogenic germline variants, and the current insurer is Cigna. This scenario is clinically plausible, as rare ovarian cancers in adolescence can be associated with hereditary cancer syndromes and de-emphasizes a need for multiple sequential tests while leveraging genetic counseling and comprehensive sequencing to guide management."
    },
    {
        "id": "Case160",
        "patient_info": "Nine-year-old patient with multiple congenital anomalies is being evaluated by a family medicine physician after prior FISH testing, with whole exome sequencing ordered to pursue a diagnostic genetic explanation; the mother has a history of growth abnormalities, suggesting a possible hereditary component; a genetic counselor met with the family before testing and will provide follow-up counseling after results are received; the patient is insured by BCBS_FEP."
    },
    {
        "id": "Case556",
        "patient_info": "At 14 years of age, a patient with multiple congenital anomalies is being evaluated by a neurologist for a suspected genetic etiology. There is no prior genetic testing. The family history reveals that the patient\u2019s mother carries a pathogenic BRCA1 variant, a detail discussed with a genetic specialist. The plan is to pursue whole exome sequencing (WES) to identify potential genetic contributors to the phenotype. The case is covered by UHC, and a genetic counselor has discussed the approach and follow-up with the family. The aim is to clarify the diagnosis, guide management, and inform surveillance strategies based on the results."
    },
    {
        "id": "Case542",
        "patient_info": "At 38 weeks\u2019 gestation, a fetus with multiple congenital abnormalities affecting different organ systems is being evaluated by an oncologist. Whole exome sequencing (WES) is planned to identify potential genetic etiologies, following prior FISH testing that was non-diagnostic. The family history includes a mother with pancreatic cancer, which informs consideration of cancer-susceptibility genes, though no genetic counseling note is documented. The case is insured by UHC."
    },
    {
        "id": "Case805",
        "patient_info": "A 27-year-old patient with multiple congenital anomalies not specific to a well-delineated genetic syndrome presents for genetic evaluation. There is no prior genetic testing. The evaluation is being led by a Primary Care Physician, with a plan to perform whole-exome sequencing (WES) and follow up with the genetic counselor who has seen the patient multiple times. The family history is notable for a sibling who experienced a Brief Resolved Unexplained Event with altered level of responsiveness, cyanosis, pallor, and irregular breathing. The patient is insured by Cigna. This workup aligns with the nonspecific congenital phenotype in a young adult and the documented utilization of WES, with post-test counseling anticipated through the genetic counselor."
    },
    {
        "id": "Case499",
        "patient_info": "At 1 year of age, an infant with hypotonia is being evaluated by a neonatologist; prior CMA was non-diagnostic, and whole-genome sequencing is planned to identify a possible genetic etiology. There is a first-degree family history with the mother having a history of growth abnormality such as short stature, suggesting a hereditary contributor. The evaluation is conducted under UnitedHealthcare (UHC) insurance, and no genetic counseling has yet been conducted. The plan includes pursuing WGS as the primary test to clarify diagnosis and guide management and surveillance as warranted by the findings."
    },
    {
        "id": "Case881",
        "patient_info": "Two-week-old neonate with intellectual disability is referred for genetic evaluation; prior FISH testing was non-diagnostic. Whole-genome sequencing has been ordered by a cardiologist, with a genetic counselor seen before testing and planned to follow up after results. The family history is notable for a parent or sibling with unexplained developmental regression, unrelated to autism or epilepsy. The case is insured through BCBS_FEP."
    },
    {
        "id": "Case583",
        "patient_info": "At 7 weeks of age, an infant is being evaluated by a Developmental Pediatrician for suspected global developmental delay, with a family history noting a sibling also affected by global developmental delay; prior FISH testing was non-diagnostic, and whole-genome sequencing is planned to pursue a genetic etiology, with care coordination documented under UHC insurance, while no genetic counseling has been documented in the chart."
    },
    {
        "id": "Case129",
        "patient_info": "A 12-year-old patient with a complex neurodevelopmental disorder and autism is being evaluated by a neurologist for a genetic workup; prior chromosomal microarray (CMA) was non-diagnostic, and whole-genome sequencing (WGS) is planned to identify a potential genetic etiology; there is a maternal history of Long QT syndrome, no genetic counseling has been documented, and the case is covered by UHC."
    },
    {
        "id": "Case681",
        "patient_info": "At 1 year of age, a patient with meconium ileus is being evaluated after a prior CMA test that was non-diagnostic, with whole-genome sequencing now ordered by an oncologist to pursue a broad genetic explanation. The family history includes a first-degree relative with dystonia, ataxia, or other neuromuscular disorders. The patient is insured through UHC. No genetic counseling has been documented as part of the current plan."
    },
    {
        "id": "Case609",
        "patient_info": "NO\nChild/adolescent with a neonatologist is not allowed."
    },
    {
        "id": "Case732",
        "patient_info": "The 19-year-old female patient has a personal history of breast cancer diagnosed at a young age and a mother diagnosed with breast cancer before age 50; in addition, a first-degree relative has laboratory abnormalities suggestive of an inborn error of metabolism. A pediatric neurologist ordered whole-genome sequencing to evaluate for a genetic etiology, following prior karyotype testing that was non-diagnostic. The chart notes no genetic counseling is documented, and the patient is covered by BCBS_FEP."
    },
    {
        "id": "Case135",
        "patient_info": "At 1 year of age, a patient with intellectual disability of moderate to profound severity, a diagnosis typically established by age 18, is undergoing genetic evaluation. Prior karyotype testing has been non-diagnostic. The evaluation was ordered by a neonatologist, and whole-genome sequencing has been planned, with a genetic counselor having discussed pre-test counseling with a genetic specialist and arranging follow-up. There is a paternal uncle with metastatic prostate cancer in the family. The case is insured through UHC."
    },
    {
        "id": "Case837",
        "patient_info": "Five-year-old patient with congenital choanal atresia is undergoing genetic evaluation; prior Fragile X testing was non-diagnostic, and whole-genome sequencing is being ordered to explore a genetic basis. The ordering clinician is an oncologist, and the family history includes an arrhythmia in the patient\u2019s mother, which informs risk assessment and counseling. The patient is insured through UHC, and there is no documented genetic counseling to date."
    },
    {
        "id": "Case132",
        "patient_info": "At 7 weeks of age, a general pediatrician ordered whole-genome sequencing to evaluate suspected intellectual disability after a chromosomal microarray analysis was non-diagnostic; the infant\u2019s mother has ovarian carcinoma, raising concern for possible inherited cancer susceptibility, and a genetic counselor was consulted before testing with plans for post-result follow-up, with the procedure covered by UHC insurance."
    },
    {
        "id": "Case887",
        "patient_info": "NO\nBRUE is a pediatric diagnosis, so assigning it to a 47-year-old makes the scenario unrealistic."
    },
    {
        "id": "Case426",
        "patient_info": "Fifteen-year-old female presents with lobular breast cancer, prompting evaluation for a hereditary cancer syndrome given a first-degree relative with diffuse gastric cancer; the family history also includes a first-degree relative with autism spectrum disorder. The patient is insured through Cigna, and the initial evaluation was ordered by a gynecologist, with no prior genetic testing performed. BRCA1/BRCA2 genetic testing has been ordered to guide risk assessment and potential surveillance, and no genetic counseling is documented in the record at this time."
    },
    {
        "id": "Case131",
        "patient_info": "A 3-week-old infant with hypotonia presented to a primary care physician who ordered BRCA1/2 testing after an earlier FISH study was non-diagnostic; the family reports a first-degree relative, the mother, with intellectual disability diagnosed by age 18, and they have consulted a genetic counselor multiple times, with BRCA1/2 testing being pursued under a Cigna insurance plan and ongoing genetic counseling follow-up arranged."
    },
    {
        "id": "Case251",
        "patient_info": "At 27 years of age, a patient with congenital choanal atresia was referred for germline BRCA1/2 testing to evaluate inherited cancer risk, ordered by a Family Medicine Physician, with no prior genetic testing documented. The family history reveals a father with metastatic prostate cancer, which raises concern for an inherited cancer syndrome and supports testing for cancer susceptibility. The patient is insured through UHC."
    },
    {
        "id": "Case157",
        "patient_info": "A 1-year-old child with moderate to profound intellectual disability diagnosed by early childhood evaluation has undergone prior karyotype testing that was non-diagnostic. The mother has laboratory abnormalities suggestive of an inborn error of metabolism. The Developmental Pediatrician ordered BRCA1/2 genetic testing to evaluate a potential hereditary cancer predisposition, with no mention of genetic counseling in the record. The patient is insured by UHC."
    },
    {
        "id": "Case836",
        "patient_info": "A 4\u2011week\u2011old infant presents with Hirschsprung disease and a prior chromosomal microarray that was non-diagnostic; the evaluation was led by a Family Medicine Physician with ongoing input from a genetic counselor whom the family has seen multiple times. Given a brother with intellectual disability diagnosed by age 18, genetic risk discussions were pursued, and a BRCA1/2 test was ordered as part of the genetic workup, with the patient insured through UHC."
    },
    {
        "id": "Case762",
        "patient_info": "NO\nBRCA1/2 testing in a fetus at 20 weeks gestation is unrealistic for prenatal testing and not supported by standard prenatal testing scope."
    },
    {
        "id": "Case979",
        "patient_info": "At 30 years of age, a man presenting with breast cancer is being evaluated for hereditary cancer risk, with BRCA1/2 germline testing ordered after a prior FISH study was non-diagnostic; the ordering clinician is a cardiologist, and a genetic counselor has seen him multiple times to discuss implications and plan follow-up. His sister has a family history notable for an inborn error of metabolism, and the plan includes continued genetic counseling and testing, with insurance coverage through UHC."
    },
    {
        "id": "Case22",
        "patient_info": "NO\nAn 18-year-old with metastatic, high-risk prostate cancer is biologically implausible and violates typical adult-onset cancer age expectations."
    },
    {
        "id": "Case722",
        "patient_info": "At 35 years of age, the patient has a history of hypotonia in infancy and is undergoing evaluation for hereditary cancer risk with BRCA1/2 testing planned. The order was placed by a nurse practitioner, and a genetic counselor discussed the case with a genetic specialist, with pre-test counseling documented and follow-up genetics appointment planned. A mother, the patient's first-degree relative, has a history of two or more distinct primary solid tumors, supporting testing consideration, and prior testing included FISH, which was non-diagnostic. The BRCA1/2 test is to be performed under BCBS_FEP insurance."
    },
    {
        "id": "Case943",
        "patient_info": "At 5 years of age, a child with an abnormality affecting at least one organ system and autism is evaluated after referral from a Family Medicine Physician who ordered BRCA1/2 genetic testing. Prior testing included FISH testing, which was non-diagnostic. The family history is notable for an inborn error of metabolism. A genetic counselor met with the family before testing and will visit after results are received. The patient is insured through UHC."
    },
    {
        "id": "Case908",
        "patient_info": "A 14-year-old patient presents with triple-negative breast cancer, a pediatric-onset cancer that, while rare, is biologically plausible and clinically concerning for an underlying hereditary cancer predisposition; the case is managed with input from a cardiologist who ordered BRCA1/2 testing, and prior karyotype testing has been performed and reported non-diagnostic, while genetic counseling was declined by the patient; the family history reveals a mother with a growth abnormality (e.g., short stature), a detail that further supports consideration of an inherited syndrome and ongoing genetic evaluation; this plan is pursued under Cigna insurance with BRCA1/2 testing as the primary genetic test, and the absence of prior test results is noted in the narrative."
    },
    {
        "id": "Case259",
        "patient_info": "A 1-year-old patient with coloboma is being considered for genetic testing. The family history includes a mother with a known pathogenic or likely pathogenic variant in BRCA1, BRCA2, or PALB2, suggesting potential familial cancer predisposition. Fragile X testing has been performed previously and was non-diagnostic. BRCA1/2 testing was ordered by a cardiologist for this child, and the family declined genetic counseling. The patient is insured through UHC."
    },
    {
        "id": "Case392",
        "patient_info": "Four weeks of age, a neonate with a major congenital cardiac anomaly underwent genetic evaluation after prior karyotype testing that was non-diagnostic; BRCA1/2 genetic testing was ordered as part of a broader hereditary cancer predisposition assessment. The family history includes a maternal aunt with Lynch syndrome diagnosed at age 50 or younger, suggesting potential familial cancer risk; the ordering clinician was a neurologist, and a genetic counselor had previously met with the family before testing and plans to meet again after results are received. The patient is covered by BCBS_FEP."
    },
    {
        "id": "Case99",
        "patient_info": "A 37-year-old patient presents for genetic evaluation after a congenital anomaly detected since birth; the plan includes BRCA1/2 testing to assess cancer susceptibility, ordered by a neurologist, with no prior genetic testing. There is a family history of a first-degree relative with unexplained developmental regression, unrelated to autism or epilepsy, which raises concern for a possible hereditary neurodevelopmental syndrome. A genetic counselor was seen before testing and will review results with the patient afterward. The patient is insured through Cigna."
    },
    {
        "id": "Case628",
        "patient_info": "At 62 years of age, the patient has a history of unexplained epileptic encephalopathy with onset before age three, a lifelong neurodevelopmental condition that has not yet had a defined etiologic diagnosis despite prior evaluations. The current workup includes chromosomal microarray testing labeled CMA_tumor, ordered by a Medical Geneticist, with no prior genetic testing performed. Family history is notable for an inborn error of metabolism in the patient\u2019s mother, which raises concern for a heritable metabolic or neurogenetic risk contributing to early epilepsy. Pre-test genetic counseling was conducted with a genetic specialist to review potential results, limitations, and follow-up plans. Insurance coverage is through Cigna. The plan includes follow-up discussions with the genetic counselor after testing, with results to guide future management and surveillance."
    },
    {
        "id": "Case31",
        "patient_info": "At 19 years of age, the patient presents with significant hypotonia and developmental concerns; chromosomal microarray testing (CMA) is ordered by a cardiologist to identify copy-number variants that could explain the hypotonia and developmental history, with no prior genetic testing performed. The family history includes epithelial ovarian cancer in the mother, suggesting possible hereditary cancer predisposition. A genetic counselor was seen before testing and will return after results for risk assessment and cascade testing. The plan is documented with BCBS_FEP insurance, and the test under consideration is CMA for developmental disorder; no prior results exist, and follow-up genetic counseling is planned post-results."
    },
    {
        "id": "Case418",
        "patient_info": "At 24 years of age, a patient with a documented history of epileptic encephalopathy that began before age three presents for genetic evaluation; the assessment is initiated by a nurse practitioner, with no prior genetic testing performed. A chromosomal microarray (CMA) has been ordered to identify copy-number variants that could explain the early-onset epilepsy. The patient reports a family history of long QT syndrome, and genetic counseling was declined. The patient is insured by BCBS_FEP."
    },
    {
        "id": "Case27",
        "patient_info": "At 69 years old, the patient presents with a neuromuscular syndrome featuring dystonia, ataxia, and movement abnormalities; a chromosomal microarray (CMA) was previously performed and non-diagnostic, and CMA is again being considered as part of the workup; the patient's mother has triple-negative breast cancer; the order was placed by a Family Medicine Physician and the genetic counselor declined genetic counseling; the planned testing remains CMA, with insurance coverage through BCBS_FEP."
    },
    {
        "id": "Case792",
        "patient_info": "A 19-year-old with a history of multiple congenital anomalies was referred by a family medicine physician for chromosomal microarray testing to evaluate a developmental-disorder etiology; prior CMA performed in childhood was non-diagnostic. The patient has a sibling with global developmental delay, which raises concern for potential hereditary involvement, and a genetic counselor discussed the case with a genetic specialist. The plan is to proceed with CMA for developmental-disorder assessment under the patient\u2019s UHC insurance, with ongoing counseling and consideration of additional testing if CMA remains non-diagnostic."
    }
]